Balversa™ (erdafitinib) – New drug approval
April 12, 2019 - The FDA announced the approval of Janssen’s Balversa (erdafitinib), for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has susceptible fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations, and progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
Top